

SESSION OF 2011

SUPPLEMENTAL NOTE ON HOUSE BILL NO. 2023

As Amended by House Committee on
Corrections and Juvenile Justice

Brief*

HB 2023 would amend KSA 65-4105, 65-4107, 65-4109, 65-4111, and 65-4113, which govern the scheduling of controlled substances, to bring Kansas' law into agreement with the federal schedule. Specifically, the bill would add to the list of controlled substances included in:

- Schedule I: 4-Bromo-2,5-dimethoxyphenethylamine; 2,5-Dimethoxy-4(n)-propylthiopenethylamine (2C-7); Alpha-methyltryptamine, aka AMT; and 5-methoxy-N, N-diisopropyltryptamine (5-MeO-DIPT).
- Schedule II: Dihydroetorphine; Oripavine; Remifen-antil; Tapentadol; and Lisdexamfetamine.
- Schedule III: Embutramide, and any material, compound, mixture, or preparation containing Buprenorphine, which was previously a schedule V controlled substance.
- Schedule IV: Dichoralphenazone; Fospropofol; and Zopiclone.
- Schedule V: Lacosamide [(R)-2-acetoamido-N-benzyl-3-methoxy-propionamide, and Pregabalin [(S)-3-(aminomethyl)-5-methylhexanoic acid, 2782.

*Supplemental notes are prepared by the Legislative Research Department and do not express legislative intent. The supplemental note and fiscal note for this bill may be accessed on the Internet at <http://www.kslegislature.org>

Background

In the House Committee on Corrections and Juvenile Justice, a representative of the Kansas Board of Pharmacy, who also requested introduction of HB 2023, appeared in support of the bill. No opponents were present at the hearing. The Committee made technical amendments to the bill and recommended it favorably for passage as amended.

A fiscal note was not available for the bill at the time this supplemental note was drafted.